Close Menu

NEW YORK (GenomeWeb) – Variantyx said today that it is integrating its clinical whole genome testing pipeline with FDNA’s Face2Gene clinical suite of phenotyping applications.

The integration enables clinicians to send information directly to Variantyx about the phenotypes, syndromes, and genes that correlate with a patient’s facial and clinical analysis. This would speed analysis and improve upon variant interpretation, Variantyx said.

To read the full story....

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.

Don't have a 360Dx or GenomeWeb account?
Register for Free.

Sponsored by

Antibody testing is expected to play an important role in the management of the COVID-19 pandemic. 


As worldwide COVID-19 cases continue to rise, there is a significant need to increase testing and population surveillance capacity.

Sponsored by

As cases of COVID-19 continued to grow this spring and summer in the US, so too did the number of Emergency Use Authorizations from the FDA for clinical diagnostic tests aimed at detecting current and past infections.